|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 23 |
| 2 | Multifunctional lymph-targeted platform based Mn@mSiO2 nanocomposites: Combining PFOB dual-mode imaging and DOX for cancer diagnose treatment on for and显示文摘 | Tian Liu Guangyu Wu Jiejun Cheng Qing Lu Yanjie Yao Zhenjing Liu Dongchen Zhu Juan Zhou Jianrong Xu Jun Zhu Dannong He | 2016 | Nano Research2016，9，2： | 11 |
| 3 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 3 |
| 4 | Hyaluronic Acid-Gadolinium Complex Nanospheres as Lymphatic System-Specific Contrast Agent for Magnetic Resonance Imaging显示文摘一个新奇 MRI 对比代理人,玻尿的酸金轧建筑群(HA-Gd-DTPA ) nanospheres,被玻尿的酸金轧建筑群和他们的集会的合成准备。物理化学的性质被描绘,并且在 vitro 并且在 vivo 的淋巴的指向也被评估。有合适、稳定的物理化学的性质的 HA-Gd-DTPA nanospheres 能在淋巴的指向学习的 vivo 被用于的结果表演。而且, HA-Gd-DTPA nanospheres 比 Magnevist 的在兔子有在血容器和淋巴容器之间的显然更高的松驰效率和 MRI 对比。因此,新奇 MRI 对比代理人能被淋巴的系统有选择地收起并且在淋巴的系统把代理人用作一个潜在的 MRI 对比。 | Guangyu Wu Huajuan Zhang Zufeng Zhan Qing Lu Jiejun Cheng Jianrong Xu Jun Zhu | 2015 | Chinese Journal of Chemistry2015，33，10： | 2 |
| 5 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 6 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 7 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 8 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 9 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 10 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 11 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 12 | Chinese experts' consensus on diagnosis, prevention, and treatment of chemotherapyinduced hepatotoxicity显示文摘Overview Drug-induced liver injury(DILI)due to acetaminophen overdose and idiosyncratic drug reactions usually occurs 5–90 days after exposure to the causative drug.Ninety percent of DILI cases are acute.As one of the most common non-infectious liver diseases,DILI represents a growing challenge for clinicians.According to data from WHO[1],DILI is the fifth leading cause of liver disease mortality.In China,DILI accounts for 1%–5%of hospitalized patients with liver diseases,10%of patients | Wenxi Yu Yuanjue Sun Yang Yao Shiying Yu Feng Yu Jun Ma Jiejun Wang Jifeng Feng Guoping Sun Jiliang Yin Yuan Chen Li Zhang Mei Hou Xianglin Yuan Jun Liang Cheng Huang Guangru Xie Qing Xie Wen Xie | 2015 | The Chinese-German Journal of Clinical Oncology2015，14，1： | 1 |
| 13 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial显示文摘 | Ann-Lii Cheng Yoon-Koo Kang Zhendong Chen Chao-Jung Tsao Shukui Qin Jun Suk Kim Rongcheng Luo Jifeng Feng Shenglong Ye Tsai-Sheng Yang Jianming Xu Yan Sun Houjie Liang Jiwei Liu Jiejun Wang Won Young Tak Hongming Pan Karin Burock Jessie Zou Dimitris Volio | 2009 | Lancet Oncology2009，，1： | 1 |
| 14 | A chemophotothermal and targeting multifunctional nanoprobe with a tumor-diagnosing ability显示文摘为癌症的诊断和治疗的多功能的 nanoparticles 的发展是最近的年里的研究的一个焦点。由于 chemophotothermal 的优秀性质,指向的治疗和肿瘤由磁性的回声(先生) 伴随了或计算了断层摄影术(CT ) 成像, mesoporous 硅石广泛地被用于诊断搬运人的肿瘤。然而,更集中于化疗的以前的研究把治疗学的策略与 photothermal 相结合,但是忽略了对肿瘤的直觉的评价。在这个工作,我们报导由 hyaluronic-acid-modified 金牌 Nanorods@mSiO2@Mn@DOX (GNR@MMH@DOX ) nanoparticles 组成的新奇 nanoprobe,它认识到治疗学和成像的多功能的集成。没有一位种子先锋, Au nanorods (GNR ) 被一个水洗澡方法综合,然后顺序与 mesoporous 硅石修改了,与 Mn 2+, 做了并且与在一个答案的 doxorubicin 装载了。在 vitro 并且在 vivo,试金验证了他们指向到受体 CD44 的大 biocompatibility,好稳定性,和吸引人的特性,它是癌症房间上的 overexpressed。另外, GNR@MMH nanoparticles 证明了是与商业对比代理人相比的一个更可区分的 CT/MR 成像对比。文章为 CT/MR 成像和肿瘤的 photothermal 治疗表明有希望的作文,给进恶意的肿瘤的不同类型的诊断和治疗的新卓见。 | Niannian Li Jiejun Cheng Ying Zhang Jie Wang Gang Huang Jun Zhu Dannong He | 2018 | Nano Research2018，11，8： | 0 |
| 15 | Preparation of Polymer-Functionalized Iron Oxide Nanoparti-cles and Their Biomedical Properties显示文摘有狭窄的尺寸分布的 Superparamagnetic 氧化铁 nanoparticles 被一个灵巧的一个壶成功地在大规模准备合成方法面对吸水的聚合物,例如聚乙烯乙二醇二酸(HOOC-PEG-COOH ) 并且 poly (丙烯酸的酸)( 泛美航空公司) 。同样准备的产品被粉末 X 光检查衍射(XRD ) 详细调查, thermogravimetric 分析(TGA ) ,传播电子显微镜学(TEM ) ,高分辨率的传播电子显微镜学(HRTEM ) ,散布,并且颤动的动态光(DLS ) 样品磁强计(VSM ) 。在聚合物和氧化铁 nanoparticles 之间的相互作用用 Fourier 被调查转变红外线的 spectrometry (英尺红外) 。结果证明聚合物能被分别地衔接协作和 monodentate 时尚依附到氧化铁 nanoparticle 的表面上。相互作用显著地影响氧化铁 nanoparticle 性质,例如 XRD 衍射紧张,水动力学直径,等电位的点,和浸透磁化。而且,结果在显示的 vitro 实验,那铁 oxide-PEG-COOH nanoparticle 比氧化铁更细胞毒素 -- 泛美航空公司 nanoparticle 由于不同协调模式。 | Qing Lu Daixu Wei Juan Zhou Jianrong Xu Jiejun Cheng Jun Zhu | 2013 | Chinese Journal of Chemistry2013，31，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员